Enzalutamide"'"'''

Enzalutamide
ENZULAMIDE 40  is an antiandrogen medication used in the treatment of prostate cancer. It is marketed under the brand name Xtandi.
Here are some important points to know about ENZULAMIDE 40 :
Indications: ENZULAMIDE 40  is primarily used in the treatment of advanced prostate cancer that has spread to other parts of the body (metastatic) and is resistant to medical or surgical castration. It is prescribed for patients who have previously received hormone therapy.
Mechanism of Action: ENZULAMIDE 40  is an androgen receptor inhibitor. It works by blocking the binding of androgens (male hormones), such as testosterone, to the androgen receptors in prostate cancer cells. By inhibiting this interaction, ENZULAMIDE 40  helps to suppress the growth and spread of prostate cancer cells.
Dosage: ENZULAMIDE 40  is taken orally as capsules. The dosage and treatment schedule will be determined by the prescribing healthcare professional. It is usually taken once daily with or without food. It's important to follow the specific instructions provided by the healthcare professional or included with the medication.
Side Effects: Common side effects of ENZULAMIDE 40  may include fatigue, hot flashes, hypertension (high blood pressure), diarrhea, nausea, and musculoskeletal pain. Serious side effects, although rare, can occur and may include seizures, falls or fractures, and allergic reactions. It is important to promptly report any concerning side effects to a healthcare provider.
Precautions and Warnings: ENZULAMIDE 40  may interact with other medications, so it's important to disclose all other medications, supplements, or herbal products you are taking to your healthcare provider. ENZULAMIDE 40  should not be used in women, as it can cause harm to a developing fetus if taken during pregnancy. Additionally, men who are sexually active and have a partner of reproductive potential should use effective contraception during treatment and for three months after the last dose.
Monitoring: Regular monitoring of prostate-specific antigen (PSA) levels and other laboratory parameters may be necessary during treatment with ENZULAMIDE 40  to evaluate the response to therapy and monitor for any potential adverse effects.
For further information please contact: info@sterispharma.com Order Now - https://www.sterisonline.com/product/enzulamide-40-133657